China Automotive Systems Reports 19.9% Increase in Net Sales in First Quarter of 2025

China Automotive Systems Reports 19.9% Increase in Net Sales in First Quarter of 2025

WUHAN, China, May 14, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (NASDAQ: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced its unaudited financial results for the first...

iotaMotion Announces First Use of Robotic-Assisted Cochlear Implant Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

iotaMotion Announces First Use of Robotic-Assisted Cochlear Implant Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is in use...

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections Demonstrated its Efficacy and Safety through previous Clinical Trials Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May...

Transforming Cloud Brokerage in ASEAN: AXLGEAR Set to Launch in May 2025

Transforming Cloud Brokerage in ASEAN: AXLGEAR Set to Launch in May 2025

KUALA LUMPUR and TOKYO, May 13, 2025 /PRNewswire/ -- AXLBIT ASIA SDN. BHD., headquartered in Kuala Lumpur, Malaysia, and a wholly owned subsidiary of AXLBIT, Inc. (a KDDI Group affiliate based in Tokyo, Japan), will launch AXLGEAR -- a cloud-based...

Aetina Showcases Full-Stack Edge AI Innovations at COMPUTEX 2025, Driving Generative AI and Intelligent Applications at the Edge

Aetina Showcases Full-Stack Edge AI Innovations at COMPUTEX 2025, Driving Generative AI and Intelligent Applications at the Edge

TAIPEI, May 12, 2025 /PRNewswire/ -- Aetina, a leading provider of edge AI solutions, is set to showcase its comprehensive edge AI computing portfolio at COMPUTEX 2025 (May 20th –23rd, Taipei Nangang Exhibition Center, Hall 1, Booth J0118). The...

Xailient and Konami to Debut Privacy-Safe Biometric Innovation for Table Games at G2E Asia 2025

Xailient and Konami to Debut Privacy-Safe Biometric Innovation for Table Games at G2E Asia 2025

MACAU, May 9, 2025 /PRNewswire/ -- Xailient Inc., the world leader in privacy-safe computer vision AI, today announced the debut of a groundbreaking biometric innovation in partnership with global gaming leader Konami Gaming, Inc. At G2E Asia 2025,...

Autoliv Announces Results of 2025 Annual Stockholders Meeting

Autoliv Announces Results of 2025 Annual Stockholders Meeting

DETROIT, May 9, 2025 /PRNewswire/ -- Autoliv, Inc., (NYSE: ALV) (SSE: ALIV.sdb), the worldwide leader in automotive safety systems, today announced the results of its annual general meeting of stockholders held on May 8, 2025. Annual General Meeting...

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting

CHICAGO, May 7, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research...

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as...

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

  • 1
  • ...
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • ...
  • 49
  • menu
    menu